Thr269
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.1.1
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr269  -  SMAD4 (human)

Site Information
HNStTTWtGSRtAPY   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 36694100

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 1 ) , mutation of modification site ( 1 ) , phospho-antibody ( 1 ) , western blotting ( 1 )
Disease tissue studied:
breast cancer ( 1 ) , breast adenocarcinoma ( 1 ) , breast cancer, triple negative ( 1 )
Relevant cell line - cell type - tissue:
293 (epithelial) ( 1 ) , 3T3 (fibroblast) ( 1 ) , HaCaT (keratinocyte) ( 1 ) , L Wnt-3A ( 1 ) , MDA-MB-468 (breast cell) ( 1 )

Upstream Regulation
Putative in vivo kinases:
GSK3B (human) ( 1 )
Treatments:
BIO ( 1 ) , EGF ( 1 ) , FGF2 ( 1 ) , lithium ( 1 ) , MG132 ( 1 ) , U0126 ( 1 ) , Wnt3a ( 1 )

Downstream Regulation
Effects of modification on SMAD4:
molecular association, regulation ( 1 ) , protein degradation ( 1 ) , ubiquitination ( 1 )
Effects of modification on biological processes:
carcinogenesis, inhibited ( 1 ) , signaling pathway regulation ( 1 ) , transcription, inhibited ( 1 )
Induce interaction with:
BTRC (human) ( 1 )

References 

1

Demagny H, Araki T, De Robertis EM (2014) The Tumor Suppressor Smad4/DPC4 Is Regulated by Phosphorylations that Integrate FGF, Wnt, and TGF-β Signaling. Cell Rep 9, 688-700
25373906   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2019 Cell Signaling Technology, Inc.